Phathom Pharmaceuticals Ownership 2024 | Who Owns Phathom Pharmaceuticals Now?
Institutional Ownership
91.19%
Insider Ownership
8.99%
Retail Ownership
-0.18%
Institutional Holders
117.00
Phathom Pharmaceuticals Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 17.64% | 4.53% | 10,109,279 | - | - | 107,360,543 | Mar 31, 2024 |
| MEDICXI VENTURES MANAGEMENT (JERSEY) LTD | 13.03% | 17.65% | 7,464,572 | 3,703,703 | 98.48% | 79,273,755 | Mar 31, 2024 |
| CARLYLE GROUP INC. | 6.10% | 2.34% | 3,496,808 | - | - | 37,101,133 | Mar 31, 2024 |
| INVESCO LTD. | 5.51% | 0.01% | 3,159,789 | -7,864 | -0.25% | 33,556,959 | Mar 31, 2024 |
| BLACKROCK INC. | 4.79% | 0.00% | 2,745,380 | 66,489 | 2.48% | 29,155,935 | Mar 31, 2024 |
| ENSIGN PEAK ADVISORS, INC | 3.98% | 0.04% | 2,280,000 | - | - | 24,213,600 | Mar 31, 2024 |
| VANGUARD GROUP INC | 3.45% | 0.00% | 1,979,113 | 22,684 | 1.16% | 21,018,180 | Mar 31, 2024 |
| NEA MANAGEMENT COMPANY, LLC | 3.42% | 1.29% | 1,960,169 | - | - | 20,816,995 | Mar 31, 2024 |
| AVIDITY PARTNERS MANAGEMENT LP | 3.03% | 0.59% | 1,735,000 | 13,420 | 0.78% | 18,425,700 | Mar 31, 2024 |
| 683 CAPITAL MANAGEMENT, LLC | 2.88% | 1.28% | 1,650,000 | 370,000 | 28.91% | 17,523,000 | Mar 31, 2024 |
| JENNISON ASSOCIATES LLC | 2.88% | 0.01% | 1,647,697 | 1,647,697 | 100.00% | 17,498,542 | Mar 31, 2024 |
| GILDER GAGNON HOWE & CO LLC | 1.78% | 0.14% | 1,017,617 | -437,515 | -30.07% | 10,807,093 | Mar 31, 2024 |
| PROPEL BIO MANAGEMENT, LLC | 1.52% | 5.38% | 869,927 | 426,880 | 96.35% | 9,238,625 | Mar 31, 2024 |
| DECHENG CAPITAL LLC | 1.48% | 1.21% | 850,000 | - | - | 9,027,000 | Mar 31, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.31% | 0.00% | 751,379 | 16,106 | 2.19% | 7,980,977 | Mar 31, 2024 |
| CATALYS PACIFIC, LLC | 1.26% | 5.18% | 721,962 | - | - | 7,667,236 | Mar 31, 2024 |
| STATE STREET CORP | 1.25% | 0.00% | 717,201 | 29,364 | 4.27% | 7,616,675 | Mar 31, 2024 |
| KENNEDY CAPITAL MANAGEMENT LLC | 1.00% | 0.13% | 572,336 | 360 | 0.06% | 6,078,208 | Mar 31, 2024 |
| GW&K INVESTMENT MANAGEMENT, LLC | 0.99% | 0.05% | 568,026 | 6,536 | 1.16% | 6,032,000 | Mar 31, 2024 |
| WOODLINE PARTNERS LP | 0.99% | 0.06% | 566,439 | -529,682 | -48.32% | 6,015,582 | Mar 31, 2024 |
Phathom Pharmaceuticals's largest institutional shareholder is FRAZIER LIFE SCIENCES MANAGEMENT, L.P., holding 17.64% of the company's total share outstanding, currently valued at $107.36M. The top 10 institutional shareholders own together 63.85% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| MEDICXI VENTURES MANAGEMENT (JERSEY) LTD | 13.03% | 17.65% | 7,464,572 | 3,703,703 | 98.48% | 79,273,755 | Mar 31, 2024 |
| PROPEL BIO MANAGEMENT, LLC | 1.52% | 5.38% | 869,927 | 426,880 | 96.35% | 9,238,625 | Mar 31, 2024 |
| CATALYS PACIFIC, LLC | 1.26% | 5.18% | 721,962 | - | - | 7,667,236 | Mar 31, 2024 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 17.64% | 4.53% | 10,109,279 | - | - | 107,360,543 | Mar 31, 2024 |
| CHECKPOINT CAPITAL L.P. | 0.78% | 3.16% | 445,161 | 85,715 | 23.85% | 4,727,610 | Mar 31, 2024 |
| CARLYLE GROUP INC. | 6.10% | 2.34% | 3,496,808 | - | - | 37,101,133 | Mar 31, 2024 |
| SATURN V CAPITAL MANAGEMENT LLC | 0.87% | 2.13% | 500,987 | 340,912 | 212.97% | 5,320,482 | Mar 31, 2024 |
| GHOST TREE CAPITAL, LLC | 0.85% | 1.43% | 485,000 | 99,759 | 25.90% | 5,150,700 | Mar 31, 2024 |
| PENN MUTUAL ASSET MANAGEMENT, LLC | 0.11% | 1.42% | 62,802 | - | - | 666,957 | Mar 31, 2024 |
| NEA MANAGEMENT COMPANY, LLC | 3.42% | 1.29% | 1,960,169 | - | - | 20,816,995 | Mar 31, 2024 |
| 683 CAPITAL MANAGEMENT, LLC | 2.88% | 1.28% | 1,650,000 | 370,000 | 28.91% | 17,523,000 | Mar 31, 2024 |
| DECHENG CAPITAL LLC | 1.48% | 1.21% | 850,000 | - | - | 9,027,000 | Mar 31, 2024 |
| STEPSTONE GROUP LP | 0.74% | 0.95% | 422,085 | - | - | 4,482,543 | Mar 31, 2024 |
| AVIDITY PARTNERS MANAGEMENT LP | 3.03% | 0.59% | 1,735,000 | 13,420 | 0.78% | 18,425,700 | Mar 31, 2024 |
| OCTAGON CAPITAL ADVISORS LP | 0.79% | 0.58% | 455,000 | 405,000 | 810.00% | 4,832,100 | Mar 31, 2024 |
| NEWTYN MANAGEMENT, LLC | 0.29% | 0.35% | 165,000 | -481,760 | -74.49% | 1,752,300 | Mar 31, 2024 |
| SIMPLIFY ASSET MANAGEMENT INC. | 0.91% | 0.33% | 521,935 | 284,000 | 119.36% | 5,542,950 | Mar 31, 2024 |
| ENTRYPOINT CAPITAL, LLC | 0.03% | 0.18% | 19,380 | 19,380 | 100.00% | 205,816 | Mar 31, 2024 |
| GILDER GAGNON HOWE & CO LLC | 1.78% | 0.14% | 1,017,617 | -437,515 | -30.07% | 10,807,093 | Mar 31, 2024 |
| KENNEDY CAPITAL MANAGEMENT LLC | 1.00% | 0.13% | 572,336 | 360 | 0.06% | 6,078,208 | Mar 31, 2024 |
The largest Phathom Pharmaceuticals shareholder by % of total assets is MEDICXI VENTURES MANAGEMENT (JERSEY) LTD. The company owns 7.46M shares of Phathom Pharmaceuticals (PHAT), representing 17.65% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| MEDICXI VENTURES MANAGEMENT (JERSEY) LTD | 13.03% | 17.65% | 7,464,572 | 3,703,703 | 98.48% | 79,273,755 | Mar 31, 2024 |
| JENNISON ASSOCIATES LLC | 2.88% | 0.01% | 1,647,697 | 1,647,697 | 100.00% | 17,498,542 | Mar 31, 2024 |
| PROPEL BIO MANAGEMENT, LLC | 1.52% | 5.38% | 869,927 | 426,880 | 96.35% | 9,238,625 | Mar 31, 2024 |
| OCTAGON CAPITAL ADVISORS LP | 0.79% | 0.58% | 455,000 | 405,000 | 810.00% | 4,832,100 | Mar 31, 2024 |
| 683 CAPITAL MANAGEMENT, LLC | 2.88% | 1.28% | 1,650,000 | 370,000 | 28.91% | 17,523,000 | Mar 31, 2024 |
| SATURN V CAPITAL MANAGEMENT LLC | 0.87% | 2.13% | 500,987 | 340,912 | 212.97% | 5,320,482 | Mar 31, 2024 |
| EAGLE ASSET MANAGEMENT INC | 0.53% | 0.02% | 304,839 | 304,839 | 100.00% | 3,231,293 | Mar 31, 2024 |
| SIMPLIFY ASSET MANAGEMENT INC. | 0.91% | 0.33% | 521,935 | 284,000 | 119.36% | 5,542,950 | Mar 31, 2024 |
| TWO SIGMA INVESTMENTS, LP | 0.82% | 0.01% | 467,448 | 200,591 | 75.17% | 4,964,298 | Mar 31, 2024 |
| CITADEL ADVISORS LLC | 0.22% | 0.00% | 125,645 | 114,112 | 989.44% | 1,334,350 | Mar 31, 2024 |
| MORGAN STANLEY | 0.41% | 0.00% | 237,160 | 112,609 | 90.41% | 2,518,640 | Mar 31, 2024 |
| GHOST TREE CAPITAL, LLC | 0.85% | 1.43% | 485,000 | 99,759 | 25.90% | 5,150,700 | Mar 31, 2024 |
| CHECKPOINT CAPITAL L.P. | 0.78% | 3.16% | 445,161 | 85,715 | 23.85% | 4,727,610 | Mar 31, 2024 |
| SCHONFELD STRATEGIC ADVISORS LLC | 0.25% | 0.01% | 144,700 | 83,700 | 137.21% | 1,536,714 | Mar 31, 2024 |
| WELLINGTON MANAGEMENT GROUP LLP | 0.39% | 0.00% | 223,390 | 68,999 | 44.69% | 2,372,401 | Mar 31, 2024 |
| BLACKROCK INC. | 4.79% | 0.00% | 2,745,380 | 66,489 | 2.48% | 29,155,935 | Mar 31, 2024 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.10% | 0.00% | 59,437 | 59,437 | 100.00% | 631,221 | Mar 31, 2024 |
| MILLENNIUM MANAGEMENT LLC | 0.39% | 0.00% | 225,024 | 54,980 | 32.33% | 2,389,755 | Mar 31, 2024 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.09% | 0.00% | 49,700 | 49,700 | 100.00% | 527,814 | Mar 31, 2024 |
| STATE STREET CORP | 1.25% | 0.00% | 717,201 | 29,364 | 4.27% | 7,616,675 | Mar 31, 2024 |
As of Mar 31 2024, Phathom Pharmaceuticals's largest institutional buyer is MEDICXI VENTURES MANAGEMENT (JERSEY) LTD. The company purchased 3.70M stocks of PHAT, valued at $79.27M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0.04% | 0.00% | 20,987 | -572,764 | -96.47% | 222,882 | Mar 31, 2024 |
| WOODLINE PARTNERS LP | 0.99% | 0.06% | 566,439 | -529,682 | -48.32% | 6,015,582 | Mar 31, 2024 |
| NEWTYN MANAGEMENT, LLC | 0.29% | 0.35% | 165,000 | -481,760 | -74.49% | 1,752,300 | Mar 31, 2024 |
| GILDER GAGNON HOWE & CO LLC | 1.78% | 0.14% | 1,017,617 | -437,515 | -30.07% | 10,807,093 | Mar 31, 2024 |
| WALLEYE CAPITAL LLC | - | - | - | -202,154 | -100.00% | - | Mar 31, 2024 |
| ECOR1 CAPITAL, LLC | - | - | - | -198,480 | -100.00% | - | Mar 31, 2024 |
| AMERIPRISE FINANCIAL INC | - | - | - | -82,244 | -100.00% | - | Mar 31, 2024 |
| BIOIMPACT CAPITAL LLC | - | - | - | -70,000 | -100.00% | - | Mar 31, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | - | - | - | -65,600 | -100.00% | - | Mar 31, 2024 |
| D. E. SHAW & CO., INC. | 0.11% | 0.00% | 64,138 | -65,251 | -50.43% | 681,146 | Mar 31, 2024 |
| NUVEEN ASSET MANAGEMENT, LLC | 0.46% | 0.00% | 262,048 | -42,561 | -13.97% | 2,782,950 | Mar 31, 2024 |
| JANE STREET GROUP, LLC | 0.04% | 0.00% | 25,021 | -40,233 | -61.66% | 265,723 | Mar 31, 2024 |
| RUSSELL INVESTMENTS GROUP, LTD. | - | - | - | -39,292 | -100.00% | - | Mar 31, 2024 |
| PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | - | - | - | -38,569 | -100.00% | - | Mar 31, 2024 |
| BARCLAYS PLC | 0.05% | 0.00% | 28,199 | -21,473 | -43.23% | 300,000 | Mar 31, 2024 |
| GRAHAM CAPITAL MANAGEMENT, L.P. | - | - | - | -20,619 | -100.00% | - | Mar 31, 2024 |
| AQR CAPITAL MANAGEMENT LLC | - | - | - | -18,427 | -100.00% | - | Mar 31, 2024 |
| TOCQUEVILLE ASSET MANAGEMENT L.P. | - | - | - | -18,100 | -100.00% | - | Mar 31, 2024 |
| DYNAMIC TECHNOLOGY LAB PRIVATE LTD | - | - | - | -15,000 | -100.00% | - | Mar 31, 2024 |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | - | - | - | -14,940 | -100.00% | - | Mar 31, 2024 |
As of Mar 31 2024, Phathom Pharmaceuticals's biggest institutional seller is JACOBS LEVY EQUITY MANAGEMENT, INC. The company sold -0.57M shares of PHAT, valued at $222.88K.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| JENNISON ASSOCIATES LLC | 2.88% | 0.01% | 1,647,697 | 1,647,697 | 100.00% | 17,498,542 | Mar 31, 2024 |
| EAGLE ASSET MANAGEMENT INC | 0.53% | 0.02% | 304,839 | 304,839 | 100.00% | 3,231,293 | Mar 31, 2024 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.10% | 0.00% | 59,437 | 59,437 | 100.00% | 631,221 | Mar 31, 2024 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.09% | 0.00% | 49,700 | 49,700 | 100.00% | 527,814 | Mar 31, 2024 |
| PRELUDE CAPITAL MANAGEMENT, LLC | 0.04% | 0.01% | 22,044 | 22,044 | 100.00% | 234,107 | Mar 31, 2024 |
| ENTRYPOINT CAPITAL, LLC | 0.03% | 0.18% | 19,380 | 19,380 | 100.00% | 205,816 | Mar 31, 2024 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.02% | - | 14,100 | 14,100 | 100.00% | 149,742 | Mar 31, 2024 |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | 0.02% | 0.00% | 11,228 | 11,228 | 100.00% | 80,168 | Mar 31, 2024 |
| KLINGMAN & ASSOCIATES, LLC | 0.02% | 0.01% | 10,376 | 10,376 | 100.00% | 110,194 | Mar 31, 2024 |
| KESTRA PRIVATE WEALTH SERVICES, LLC | 0.02% | 0.00% | 10,000 | 10,000 | 100.00% | 106,200 | Mar 31, 2024 |
| FNY INVESTMENT ADVISERS, LLC | 0.01% | 0.03% | 5,000 | 5,000 | 100.00% | 53,000 | Mar 31, 2024 |
| RIGGS ASSET MANAGMENT CO. INC. | 0.00% | 0.00% | 69 | 69 | 100.00% | 733 | Mar 31, 2024 |
| NELSON, VAN DENBURG & CAMPBELL WEALTH MANAGEMENT GROUP, LLC | - | - | 7 | 7 | 100.00% | 74 | Mar 31, 2024 |
Phathom Pharmaceuticals's largest new institutional shareholder by number of shares is JENNISON ASSOCIATES LLC, purchased 1.65M shares, valued at $17.50M, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| WALLEYE CAPITAL LLC | - | - | - | -202,154 | -100.00% | - | Mar 31, 2024 |
| ECOR1 CAPITAL, LLC | - | - | - | -198,480 | -100.00% | - | Mar 31, 2024 |
| AMERIPRISE FINANCIAL INC | - | - | - | -82,244 | -100.00% | - | Mar 31, 2024 |
| BIOIMPACT CAPITAL LLC | - | - | - | -70,000 | -100.00% | - | Mar 31, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | - | - | - | -65,600 | -100.00% | - | Mar 31, 2024 |
| RUSSELL INVESTMENTS GROUP, LTD. | - | - | - | -39,292 | -100.00% | - | Mar 31, 2024 |
| PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | - | - | - | -38,569 | -100.00% | - | Mar 31, 2024 |
| GRAHAM CAPITAL MANAGEMENT, L.P. | - | - | - | -20,619 | -100.00% | - | Mar 31, 2024 |
| AQR CAPITAL MANAGEMENT LLC | - | - | - | -18,427 | -100.00% | - | Mar 31, 2024 |
| TOCQUEVILLE ASSET MANAGEMENT L.P. | - | - | - | -18,100 | -100.00% | - | Mar 31, 2024 |
| DYNAMIC TECHNOLOGY LAB PRIVATE LTD | - | - | - | -15,000 | -100.00% | - | Mar 31, 2024 |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | - | - | - | -14,940 | -100.00% | - | Mar 31, 2024 |
| ALGERT GLOBAL LLC | - | - | - | -14,920 | -100.00% | - | Mar 31, 2024 |
| QUEST PARTNERS LLC | - | - | - | -2,205 | -100.00% | - | Mar 31, 2024 |
| GROUP ONE TRADING, L.P. | - | - | - | -1,545 | -100.00% | - | Mar 31, 2024 |
| TRADITION WEALTH MANAGEMENT, LLC | - | - | - | -500 | -100.00% | - | Mar 31, 2024 |
Phathom Pharmaceuticals's largest sold out institutional shareholder by shares sold is WALLEYE CAPITAL LLC, sold -0.20M shares, valued at -, as of undefined.
Phathom Pharmaceuticals Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| PRUDENTIAL SECTOR FUNDS, INC. | 0.20% | 417,422 | 417,422 | - | Feb 29, 2024 |
| Federated Hermes MDT Series | 0.06% | 159,626 | - | - | Jan 31, 2024 |
| AIM INTERNATIONAL MUTUAL FUNDS (INVESCO INTERNATIONAL MUTUAL FUNDS) | 0.05% | 1,733,665 | -11,709 | -0.67% | Jan 31, 2024 |
| VANGUARD VALLEY FORGE FUNDS | 0.05% | 25,360 | - | - | Dec 31, 2023 |
| STATE STREET INSTITUTIONAL FUNDS | 0.03% | 24,051 | - | - | Dec 31, 2023 |
| FIDELITY ADVISOR SERIES VII | 0.02% | 154,200 | - | - | Jan 31, 2024 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.01% | 5,004 | 628 | 14.35% | Dec 31, 2023 |
| QUANTITATIVE MASTER SERIES LLC | 0.01% | 56,253 | 3,898 | 7.45% | Dec 31, 2023 |
| AMG Funds IV | 0.01% | 19,748 | -200 | -1.00% | Jan 31, 2024 |
| ETFis Series Trust I | 0.01% | 9,189 | 1,445 | 18.66% | Jan 31, 2024 |
| VANGUARD INDEX FUNDS | 0.00% | 2,139,866 | 548,318 | 34.45% | Dec 31, 2023 |
| Nushares ETF Trust | 0.00% | 32,960 | -494 | -1.48% | Jan 31, 2024 |
| Fidelity Commonwealth Trust II | 0.00% | 22,840 | 22,840 | - | Aug 31, 2023 |
| Voya PARTNERS INC | 0.00% | 229,901 | - | - | Dec 31, 2023 |
| TIAA SEPARATE ACCOUNT VA 1 | 0.00% | 575 | - | - | Dec 31, 2023 |
| Humankind Benefit Corp | 0.00% | 54 | - | - | Dec 31, 2023 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 331,767 | 10,477 | 3.26% | Feb 29, 2024 |
| JANUS INVESTMENT FUND | 0.00% | 421,939 | - | - | Dec 31, 2023 |
| MASSMUTUAL PREMIER FUNDS | 0.00% | 36,710 | -2,526 | -6.44% | Dec 31, 2023 |
| Calvert Variable Products, Inc. | 0.00% | 3,095 | - | - | Dec 31, 2023 |
| VANGUARD EXPLORER FUND | 0.00% | 15,061 | - | - | Jan 31, 2024 |
| GOLDMAN SACHS VARIABLE INSURANCE TRUST | 0.00% | 3,968 | - | - | Dec 31, 2023 |
| SCHWAB STRATEGIC TRUST | 0.00% | 181,708 | 15,421 | 9.27% | Feb 29, 2024 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 24,407 | - | - | Dec 31, 2023 |
| OHIO NATIONAL FUND INC | 0.00% | 14,533 | - | - | Dec 31, 2023 |
| Principal Exchange-Traded Funds | 0.00% | 6,953 | -572 | -7.60% | Mar 31, 2024 |
| Chartwell Funds | 0.00% | 11,613 | 6,503 | 127.26% | Jun 30, 2022 |
| NATIONWIDE VARIABLE INSURANCE TRUST | 0.00% | 61,979 | 52,379 | 545.61% | Dec 31, 2023 |
| Voya VARIABLE PORTFOLIOS INC | 0.00% | 12,843 | - | - | Dec 31, 2023 |
| VANGUARD WORLD FUND | 0.00% | 97,060 | 3,983 | 4.28% | Feb 29, 2024 |
| STATE STREET VARIABLE INSURANCE SERIES FUNDS INC | 0.00% | 1,676 | -580 | -25.71% | Dec 31, 2023 |
| TIAA-CREF LIFE FUNDS | 0.00% | 764 | - | - | Dec 31, 2023 |
| Trust for Advised Portfolios | 0.00% | 5,101 | - | - | Dec 31, 2023 |
| MFS VARIABLE INSURANCE TRUST III | 0.00% | 4,093 | - | - | Dec 31, 2023 |
| EQ ADVISORS TRUST | 0.00% | 226,904 | 10,683 | 4.94% | Dec 31, 2023 |
| Fidelity Rutland Square Trust II | 0.00% | 229,213 | - | - | Feb 29, 2024 |
| AIM VARIABLE INSURANCE FUNDS (INVESCO VARIABLE INSURANCE FUNDS) | 0.00% | 393,717 | -268 | -0.07% | Dec 31, 2023 |
| SunAmerica Specialty Series | 0.00% | 89 | - | - | Apr 30, 2021 |
| VARIABLE INSURANCE PRODUCTS FUND II | 0.00% | 1,638 | -254 | -13.42% | Dec 31, 2023 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 10,700 | - | - | Dec 31, 2023 |
| PUTNAM ASSET ALLOCATION FUNDS | 0.00% | 252 | - | - | Feb 29, 2024 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 1,939 | - | - | Feb 29, 2024 |
| COLLEGE RETIREMENT EQUITIES FUND | 0.00% | 121,569 | 16,073 | 15.24% | Dec 31, 2023 |
| RUSSELL INVESTMENT FUNDS | 0.00% | 5,635 | 3,385 | 150.44% | Dec 31, 2023 |
| VANGUARD SCOTTSDALE FUNDS | 0.00% | 142,437 | 21,630 | 17.90% | Feb 29, 2024 |
| SA FUNDS INVESTMENT TRUST | 0.00% | 1,013 | - | - | Dec 31, 2023 |
| RYDEX SERIES FUNDS | 0.00% | 225 | - | - | Dec 31, 2023 |
| ProFunds | 0.00% | 457 | 187 | 69.26% | Jan 31, 2024 |
| VANGUARD WELLINGTON FUND | 0.00% | 19,548 | - | - | Feb 29, 2024 |
| MUTUAL FUND SERIES TRUST | 0.00% | 160,000 | - | - | Dec 31, 2023 |
| RUSSELL INVESTMENT CO | 0.00% | 14,134 | 8,784 | 164.19% | Jan 31, 2024 |
| VALIC Co I | 0.00% | 12,305 | 408 | 3.43% | Feb 29, 2024 |
| PACIFIC FUNDS SERIES TRUST | 0.00% | 11,488 | - | - | Mar 31, 2023 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 0.00% | 37,997 | - | - | Jan 31, 2024 |
| Meeder Funds | 0.00% | 177 | - | - | Mar 31, 2024 |
| PROSHARES TRUST | 0.00% | 8,974 | 1,361 | 17.88% | Feb 29, 2024 |
| RYDEX DYNAMIC FUNDS | 0.00% | 111 | - | - | Dec 31, 2023 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 3,535 | -45 | -1.26% | Jan 31, 2024 |
| PENN SERIES FUNDS INC | 0.00% | 700 | - | - | Dec 29, 2023 |
| GOLDMAN SACHS TRUST | 0.00% | 3,864 | - | - | Feb 29, 2024 |
| RBB FUND, INC. | 0.00% | 2,157 | - | - | Feb 29, 2024 |
| HC CAPITAL TRUST | 0.00% | 678 | - | - | Dec 31, 2023 |
| Brighthouse Funds Trust I | 0.00% | 219,817 | -455 | -0.21% | Dec 31, 2023 |
| Guggenheim Active Allocation Fund | 0.00% | 120 | - | - | Feb 29, 2024 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 39,142 | - | - | Dec 31, 2023 |
| MASTER INVESTMENT PORTFOLIO | 0.00% | 1,525 | - | - | Dec 31, 2023 |
| Direxion Shares ETF Trust | 0.00% | 2,511 | - | - | Jan 31, 2024 |
| NORTHERN FUNDS | 0.00% | 13,582 | - | - | Dec 29, 2023 |
| ALLIANZ VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 800 | - | - | Dec 31, 2023 |
| RYDEX VARIABLE TRUST | 0.00% | 15 | - | - | Dec 31, 2023 |
| LINCOLN VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 26,100 | - | - | Dec 31, 2023 |
| SPDR INDEX SHARES FUNDS | 0.00% | 2,103 | 18 | 0.86% | Dec 31, 2023 |
| PGIM ETF TRUST | 0.00% | 736 | - | - | Feb 29, 2024 |
| John Hancock Funds II | 0.00% | 161,865 | -4,165 | -2.51% | Feb 29, 2024 |
| MORGAN STANLEY PATHWAY FUNDS | 0.00% | 1,080 | - | - | Feb 29, 2024 |
| SUNAMERICA SERIES TRUST | 0.00% | 3,633 | 121 | 3.45% | Jan 31, 2024 |
| Brinker Capital Destinations Trust | 0.00% | 578 | - | - | Feb 29, 2024 |
| Goldman Sachs ETF Trust | 0.00% | 807 | -6,856 | -89.47% | Feb 29, 2024 |
| AMERICAN CENTURY ETF TRUST | 0.00% | 748 | - | - | Feb 29, 2024 |
| Invesco Exchange-Traded Fund Trust II | 0.00% | 1,526 | 540 | 54.77% | Feb 29, 2024 |
| Brighthouse Funds Trust II | 0.00% | 10,477 | - | - | Dec 31, 2023 |
| SEI INSTITUTIONAL MANAGED TRUST | 0.00% | 11,481 | - | - | Dec 31, 2023 |
| PACIFIC SELECT FUND | 0.00% | 11,811 | -359 | -2.95% | Dec 31, 2023 |
| Dimensional ETF Trust | 0.00% | 982 | - | - | Jan 31, 2024 |
| Advisors' Inner Circle Fund III | 0.00% | 32 | - | - | Jan 31, 2024 |
| SPDR SERIES TRUST | 0.00% | 69,960 | - | - | Dec 31, 2023 |
| Invesco Exchange-Traded Self-Indexed Fund Trust | 0.00% | 360 | - | - | Feb 29, 2024 |
| Bridge Builder Trust | 0.00% | 10,831 | - | - | Dec 31, 2023 |
| MASSMUTUAL SELECT FUNDS | 0.00% | 1,564 | - | - | Dec 31, 2023 |
| BlackRock Variable Series Funds, Inc. | 0.00% | 4,039 | - | - | Dec 31, 2023 |
| COLUMBIA FUNDS SERIES TRUST I | 0.00% | 3,997 | -69,014 | -94.53% | Feb 29, 2024 |
| SEI INSTITUTIONAL INVESTMENTS TRUST | 0.00% | 5,900 | - | - | Feb 29, 2024 |
Phathom Pharmaceuticals's largest mutual fund holder by % of total assets is "PRUDENTIAL SECTOR FUNDS, INC.", owning 417.42K shares, compromising 0.20% of its total assets.
Phathom Pharmaceuticals Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 31 Mar, 24 | 117 | -0.85% |
| 31 Dec, 23 | 118 | 6.31% |
| 30 Sep, 23 | 111 | 5.71% |
| 30 Jun, 23 | 105 | 23.53% |
| 31 Mar, 23 | 85 | -2.30% |
| 31 Dec, 22 | 87 | - |
| 30 Sep, 22 | 87 | -4.40% |
| 30 Jun, 22 | 91 | 10.98% |
| 31 Mar, 22 | 82 | -1.20% |
| 31 Dec, 21 | 83 | - |
| 30 Sep, 21 | 83 | 7.79% |
| 30 Jun, 21 | 77 | -7.23% |
| 31 Mar, 21 | 83 | 12.16% |
| 31 Dec, 20 | 74 | 29.82% |
| 30 Sep, 20 | 57 | -5.00% |
| 30 Jun, 20 | 60 | 27.66% |
| 31 Mar, 20 | 47 | 14.63% |
| 31 Dec, 19 | 41 | - |
As of 31 Mar 24, 117 institutions are holding Phathom Pharmaceuticals's shares, representing a decrease of -0.85% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 31 Mar, 24 | 52,249,167 | 12.12% |
| 31 Dec, 23 | 46,601,262 | 6.49% |
| 30 Sep, 23 | 43,760,270 | 2.45% |
| 30 Jun, 23 | 42,715,458 | 39.41% |
| 31 Mar, 23 | 30,640,478 | 8.11% |
| 31 Dec, 22 | 28,341,867 | -6.03% |
| 30 Sep, 22 | 30,162,032 | 10.31% |
| 30 Jun, 22 | 27,342,190 | 6.42% |
| 31 Mar, 22 | 25,692,967 | -10.08% |
| 31 Dec, 21 | 28,574,495 | 11.87% |
| 30 Sep, 21 | 25,543,686 | 2.51% |
| 30 Jun, 21 | 24,919,005 | 1.92% |
| 31 Mar, 21 | 24,449,375 | -0.25% |
| 31 Dec, 20 | 24,509,909 | 13.30% |
| 30 Sep, 20 | 21,631,992 | -0.99% |
| 30 Jun, 20 | 21,847,194 | -0.47% |
| 31 Mar, 20 | 21,949,539 | 0.63% |
| 31 Dec, 19 | 21,811,276 | - |
Phathom Pharmaceuticals (PHAT) has 52.25M shares outstanding as of 31 Mar 24, up 12.12% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 31 Mar, 24 | 91.19% | 1.35% |
| 31 Dec, 23 | 82.07% | 1.01% |
| 30 Sep, 23 | 90.23% | 0.89% |
| 30 Jun, 23 | 100.85% | 1.93% |
| 31 Mar, 23 | 72.34% | 1.54% |
| 31 Dec, 22 | 68.61% | 1.14% |
| 30 Sep, 22 | 77.70% | 1.52% |
| 30 Jun, 22 | 71.44% | 1.57% |
| 31 Mar, 22 | 67.55% | 1.13% |
| 31 Dec, 21 | 77.22% | 1.65% |
| 30 Sep, 21 | 68.48% | 1.48% |
| 30 Jun, 21 | 68.02% | 1.50% |
| 31 Mar, 21 | 67.36% | 1.30% |
| 31 Dec, 20 | 71.96% | 1.71% |
| 30 Sep, 20 | 64.83% | 1.48% |
| 30 Jun, 20 | 66.21% | 1.45% |
| 31 Mar, 20 | 67.60% | 1.50% |
| 31 Dec, 19 | 67.17% | - |
As of 31 Mar 24, Phathom Pharmaceuticals is held by 91.19% institutional shareholders, representing a 1.35% growth compared to 31 Dec 23.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 31 Mar, 24 | 53 | -28.38% |
| 31 Dec, 23 | 74 | 17.46% |
| 30 Sep, 23 | 63 | -7.35% |
| 30 Jun, 23 | 68 | 44.68% |
| 31 Mar, 23 | 47 | 20.51% |
| 31 Dec, 22 | 39 | -17.02% |
| 30 Sep, 22 | 47 | -7.84% |
| 30 Jun, 22 | 51 | 15.91% |
| 31 Mar, 22 | 44 | -13.73% |
| 31 Dec, 21 | 51 | 50.00% |
| 30 Sep, 21 | 34 | -24.44% |
| 30 Jun, 21 | 45 | 7.14% |
| 31 Mar, 21 | 42 | -6.67% |
| 31 Dec, 20 | 45 | 221.43% |
| 30 Sep, 20 | 14 | -65.00% |
| 30 Jun, 20 | 40 | 53.85% |
| 31 Mar, 20 | 26 | -36.59% |
| 31 Dec, 19 | 41 | - |
53 institutional shareholders have increased their position in PHAT stock as of 31 Mar 24 compared to 74 in the previous quarter (a -28.38% decrease).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 31 Mar, 24 | 34 | 54.55% |
| 31 Dec, 23 | 22 | -4.35% |
| 30 Sep, 23 | 23 | 21.05% |
| 30 Jun, 23 | 19 | - |
| 31 Mar, 23 | 19 | -24.00% |
| 31 Dec, 22 | 25 | 4.17% |
| 30 Sep, 22 | 24 | 9.09% |
| 30 Jun, 22 | 22 | -8.33% |
| 31 Mar, 22 | 24 | 84.62% |
| 31 Dec, 21 | 13 | -43.48% |
| 30 Sep, 21 | 23 | 64.29% |
| 30 Jun, 21 | 14 | -39.13% |
| 31 Mar, 21 | 23 | 53.33% |
| 31 Dec, 20 | 15 | -34.78% |
| 30 Sep, 20 | 23 | 228.57% |
| 30 Jun, 20 | 7 | -41.67% |
| 31 Mar, 20 | 12 | - |
| 31 Dec, 19 | - | - |
34 institutional shareholders have reduced their position in PHAT stock as of 31 Mar 24 compared to 22 in the previous quarter (a 54.55% increase).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 31 Mar, 24 | 117 | -0.85% | 52,249,167 | 12.12% | 91.19% | 1.35% | 53 | -28.38% | 34 | 54.55% |
| 31 Dec, 23 | 118 | 6.31% | 46,601,262 | 6.49% | 82.07% | 1.01% | 74 | 17.46% | 22 | -4.35% |
| 30 Sep, 23 | 111 | 5.71% | 43,760,270 | 2.45% | 90.23% | 0.89% | 63 | -7.35% | 23 | 21.05% |
| 30 Jun, 23 | 105 | 23.53% | 42,715,458 | 39.41% | 100.85% | 1.93% | 68 | 44.68% | 19 | - |
| 31 Mar, 23 | 85 | -2.30% | 30,640,478 | 8.11% | 72.34% | 1.54% | 47 | 20.51% | 19 | -24.00% |
| 31 Dec, 22 | 87 | - | 28,341,867 | -6.03% | 68.61% | 1.14% | 39 | -17.02% | 25 | 4.17% |
| 30 Sep, 22 | 87 | -4.40% | 30,162,032 | 10.31% | 77.70% | 1.52% | 47 | -7.84% | 24 | 9.09% |
| 30 Jun, 22 | 91 | 10.98% | 27,342,190 | 6.42% | 71.44% | 1.57% | 51 | 15.91% | 22 | -8.33% |
| 31 Mar, 22 | 82 | -1.20% | 25,692,967 | -10.08% | 67.55% | 1.13% | 44 | -13.73% | 24 | 84.62% |
| 31 Dec, 21 | 83 | - | 28,574,495 | 11.87% | 77.22% | 1.65% | 51 | 50.00% | 13 | -43.48% |
| 30 Sep, 21 | 83 | 7.79% | 25,543,686 | 2.51% | 68.48% | 1.48% | 34 | -24.44% | 23 | 64.29% |
| 30 Jun, 21 | 77 | -7.23% | 24,919,005 | 1.92% | 68.02% | 1.50% | 45 | 7.14% | 14 | -39.13% |
| 31 Mar, 21 | 83 | 12.16% | 24,449,375 | -0.25% | 67.36% | 1.30% | 42 | -6.67% | 23 | 53.33% |
| 31 Dec, 20 | 74 | 29.82% | 24,509,909 | 13.30% | 71.96% | 1.71% | 45 | 221.43% | 15 | -34.78% |
| 30 Sep, 20 | 57 | -5.00% | 21,631,992 | -0.99% | 64.83% | 1.48% | 14 | -65.00% | 23 | 228.57% |
| 30 Jun, 20 | 60 | 27.66% | 21,847,194 | -0.47% | 66.21% | 1.45% | 40 | 53.85% | 7 | -41.67% |
| 31 Mar, 20 | 47 | 14.63% | 21,949,539 | 0.63% | 67.60% | 1.50% | 26 | -36.59% | 12 | - |
| 31 Dec, 19 | 41 | - | 21,811,276 | - | 67.17% | - | 41 | - | - | - |
Phathom Pharmaceuticals Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
Insider Sells
All Insider Owners Trades
The last insider sell of Phathom Pharmaceuticals's stock was made by Henderson Molly on Apr 10 2024, selling 3,435 shares at $11.10 per share (valued at $38.13K). The last insider buy of PHAT was made by Parikh Asit on Nov 08 2023, buying 2,500 shares at $7.80 per share (worth $19.50K).
Phathom Pharmaceuticals Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2024 | - | 1 | - |
| Q1 2024 | 3 | 3 | 100.00% |
| Q4 2023 | 6 | 3 | 200.00% |
| Q3 2023 | 4 | 4 | 100.00% |
| Q2 2023 | 18 | 4 | 450.00% |
| Q1 2023 | 8 | 3 | 266.67% |
| Q4 2022 | - | 2 | - |
| Q3 2022 | 4 | - | - |
| Q2 2022 | 23 | - | - |
| Q1 2022 | 7 | 2 | 350.00% |
| Q4 2021 | 1 | 5 | 20.00% |
| Q3 2021 | 1 | 8 | 12.50% |
| Q2 2021 | 6 | 74 | 8.11% |
| Q1 2021 | 4 | 32 | 12.50% |
| Q4 2020 | - | 21 | - |
| Q3 2020 | 3 | - | - |
| Q2 2020 | 6 | 2 | 300.00% |
| Q1 2020 | 3 | 4 | 75.00% |
| Q4 2019 | 7 | 12 | 58.33% |
0 total buy trades, and 1 total sell trades (buy/sell ratio of 0.00%) were made by Phathom Pharmaceuticals's insiders, as of Q2 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2024 | - | 1 | - |
| Q1 2024 | - | 3 | - |
| Q4 2023 | 3 | 3 | 100.00% |
| Q3 2023 | - | - | - |
| Q2 2023 | 3 | 3 | 100.00% |
| Q1 2023 | 2 | 3 | 66.67% |
| Q4 2022 | - | 2 | - |
| Q3 2022 | - | - | - |
| Q2 2022 | 5 | - | - |
| Q1 2022 | - | 1 | - |
| Q4 2021 | - | 4 | - |
| Q3 2021 | - | 8 | - |
| Q2 2021 | - | 70 | - |
| Q1 2021 | - | 31 | - |
| Q4 2020 | - | 21 | - |
| Q3 2020 | - | - | - |
| Q2 2020 | 1 | - | - |
| Q1 2020 | 2 | 4 | 50.00% |
| Q4 2019 | 4 | - | - |
As of Q2 2024, Insider owners conducted 0 open market buy trades and 1 open market sell trades of Phathom Pharmaceuticals's stocks.
Phathom Pharmaceuticals Peer Ownership
| Ticker | Company |
|---|---|
| TERN | Terns Pharmaceuticals, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |
| CNSP | CNS Pharmaceuticals, Inc. |
| VECT | VectivBio Holding AG |
| XFOR | X4 Pharmaceuticals, Inc. |
| INZY | Inozyme Pharma, Inc. |
| IMMX | Immix Biopharma, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| GPCR | Structure Therapeutics Inc. |
| CGEM | Cullinan Oncology, Inc. |
| AMLX | Amylyx Pharmaceuticals, Inc. |
| BPMC | Blueprint Medicines Corporation |
| KNSA | Kiniksa Pharmaceuticals, Ltd. |
| AVRO | AVROBIO, Inc. |
| HEPA | Hepion Pharmaceuticals, Inc. |
| KRTX | Karuna Therapeutics, Inc. |
| LYRA | Lyra Therapeutics, Inc. |
PHAT Ownership FAQ
Who Owns Phathom Pharmaceuticals?
Phathom Pharmaceuticals is owned by institutional shareholders (91.19%), insiders (8.99%), and public (-0.18%). The largest institutional shareholder of Phathom Pharmaceuticals is FRAZIER LIFE SCIENCES MANAGEMENT, L.P. (17.64% of total shares) and the top mutual fund owner is PRUDENTIAL SECTOR FUNDS, INC. (0.20% of total shares).
Who are the major institutional shareholders of Phathom Pharmaceuticals?
Phathom Pharmaceuticals's major institutional shareholders are FRAZIER LIFE SCIENCES MANAGEMENT, L.P., MEDICXI VENTURES MANAGEMENT (JERSEY) LTD, CARLYLE GROUP INC., INVESCO LTD., and BLACKROCK INC.. The top five shareholders own together 47.08% of the company's share outstanding.
How many Phathom Pharmaceuticals shareholders are there?
As of Mar 2024, there are 117 institutional shareholders of Phathom Pharmaceuticals.
What percentage of Phathom Pharmaceuticals is owned by FRAZIER LIFE SCIENCES MANAGEMENT, L.P?
FRAZIER LIFE SCIENCES MANAGEMENT, L.P owns 10.11M shares of Phathom Pharmaceuticals, representing 17.64% of the company's total shares outstanding, valued at $107.36M (as of Mar 2024).
What percentage of Phathom Pharmaceuticals is owned by MEDICXI VENTURES MANAGEMENT (JERSEY) LTD?
As of Mar 2024, MEDICXI VENTURES MANAGEMENT (JERSEY) LTD holds 7.46M shares of Phathom Pharmaceuticals (PHAT), compromising 13.03% of the company, valued at $79.27M.
What percentage of Phathom Pharmaceuticals is owned by CARLYLE GROUP INC?
CARLYLE GROUP INC is the third largest holder of Phathom Pharmaceuticals. The company owns 3.5M of the company's shares outstanding (worth $37.1M).